Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

"Fabry Disease - Pipeline Review, H2 2013" now available at Fast Market Research


Print article Print article
2013-12-19 09:22:26 - Fast Market Research recommends "Fabry Disease - Pipeline Review, H2 2013" from Global Markets Direct, now available

Global Markets Direct's, 'Fabry Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fabry Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fabry Disease. Fabry Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated

disease.

Full Report Details at
- www.fastmr.com/prod/755149_fabry_disease_pipeline_review_h2_2013 ..

Scope

* A snapshot of the global therapeutic scenario for Fabry Disease.
* A review of the Fabry Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Fabry Disease pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Fabry Disease.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Fabry Disease pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Genzyme Corporation, Sanofi-Aventis, GlaxoSmithKline plc, Amicus Therapeutics, Inc., Protalix BioTherapeutics, Inc., Green Cross Corporation, JCR Pharmaceuticals Co., Ltd., greenovation Biotech GmbH, iBio, Inc., Neuraltus Pharmaceuticals, Inc., ISU ABXIS Co.,Ltd., Bio Sidus S.A.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fabry Disease Overview
Therapeutics Development
An Overview of Pipeline Products for Fabry Disease
Fabry Disease Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Fabry Disease Therapeutics - Products under Development by Companies
Companies Involved in Fabry Disease Therapeutics Development
Genzyme Corporation
Sanofi-Aventis
GlaxoSmithKline plc
Amicus Therapeutics, Inc.
Protalix BioTherapeutics, Inc.
Green Cross Corporation
JCR Pharmaceuticals Co., Ltd.
greenovation Biotech GmbH
iBio, Inc.
Neuraltus Pharmaceuticals, Inc.
ISU ABXIS Co.,Ltd.
Bio Sidus S.A.
Fabry Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
migalastat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRX-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JR-051 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NP-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
migalastat hydrochloride + Enzyme Replacement Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fabrazyme Biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alpha-galactosidase A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GC-1119 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Genz-682452 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GZ-402671 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(migalastat hydrochloride + agalsidase alfa) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alpha-Galactosidase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fabry Disease Therapeutics - Drug Profile Updates
Fabry Disease Therapeutics - Dormant Products
Fabry Disease - Product Development Milestones
Featured News & Press Releases
Oct 15, 2013: Genzyme to Invest $80 Million in Framingham, Mass. Site to Expand Manufacturing Capacity for Fabrazyme
Jun 17, 2013: Amicus Therapeutics Delays US Regulatory Filing For Migalastat HCl For Treatment Of Fabry Disease
Feb 15, 2013: Amicus Therapeutics Presents Additional Results From Phase III Fabry Monotherapy Study At LDN World Symposium
Feb 13, 2013: Amicus Therapeutics Presents Additional Results From Phase II Chaperone-enzyme Replacement Therapy Study For Fabry Disease At LDN World Symposium
Feb 07, 2013: Amicus Therapeutics To Present Data On Its Pharmacological Chaperones At Lysosomal Disease Network WORLD Symposium

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=755149&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com